Skip to main content

Table 1 Background Characteristics of study participants

From: Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?

 

Canada

Netherlands

Total

 

n

%

n

%

n

%

Sample

68

100%

15

100%

83

100%

Response

24

35%

9

60%

33

40%

Sex

Male

7

29%

3

33%

10

30%

Female

17

71%

6

67%

23

70%

Age

31–40

4

17%

1

11%

5

15%

41–50

11

46%

4

44%

15

45%

 > 50

9

38%

4

44%

13

39%

Primary practice Setting

Academic setting, university based

20

83%

9

100%

29

88%

Academic appointment but community based practice

2

8%

0

0%

2

6%

Solo community based practice

2

8%

0

0%

2

6%

Experience

 < 5 years

4

17%

2

22%

6

18%

6–10 years

4

17%

2

22%

6

18%

11–20 years

9

38%

4

44%

13

39%

21–30 years

7

29%

1

11%

8

24%

Clinical work (% of FTE)

 < 50%

3

13%

1

11%

4

12%

50–75%

11

46%

5

56%

16

48%

 > 75%

10

42%

3

33%

13

39%

New patients each month (n)

1–3

14

58%

8

89%

22

67%

4–6

9

38%

1

11%

10

30%

FU patients each month (n)

1–5

4

17%

0

0%

4

12%

6–25

10

42%

5

56%

15

45%

26–50

9

38%

2

22%

11

33%

 > 50

1

4%

2

22%

3

9%

Minimal treatment time after achieving CID

6 months

0

0%

4

44%

4

12%

9 months

1

4%

2

22%

3

9%

12 months

12

50%

3

33%

15

45%

15 months

2

8%

0

0%

2

6%

18 months

3

13%

0

0%

3

9%

other

6

25%

0

0%

6

18%

Discontinuation strategy

immediately stop

7

29%

1

11%

8

24%

 < 6 months tapering

10

42%

4

44%

14

42%

6–12 months tapering

2

8%

1

11%

3

9%

18–24 months tapering

1

4%

2

22%

3

9%

other

4

17%

1

11%

5

15%

  1. CID Clinically inactive disease, FTE Full-time equivalent, FU Follow-up